Investors are also concerned about Thermo Fisher's continuous decline in testing revenues due to the decline in COVID testing ...

The global Radiotherapy market is expected to grow to USD 9.62 Billion by 2030, up from USD 7.21 Billion in 2024, at a CAGR ...

Parnassus Investments, an investment management company, released the “Parnassus Growth Equity Fund” third quarter 2024 ...

Investors continue to be optimistic about Thermo Fisher due to its strategic acquisitions and string of product launches.

In a report released on December 8, Conor McNamara from RBC Capital maintained a Buy rating on Thermo Fisher (TMO – Research Report), with a ...

The stock's fall snapped a two-day winning streak.

The healthcare industry is set for growth due to the growing demand for quality treatments and ongoing progress in medical ...

Thermo Fisher Scientific's valuation multiples offer potential capital appreciation. Learn why TMO stock is a Buy, with ...

The Thermo Fisher Scientific Junior Innovators Challenge engages 65-thousand middle school students annually through affiliate science and engineering fairs nationwide. Tina ...

Thermo Fisher Scientific Inc (TMO) stock saw a modest uptick, ending the day at $537.23 which represents a slight increase of $7.87 or 1.49% from the prior close of $529.36. The stock opened at ...

The US Food and Drug Administration granted clearances to tests for infectious diseases, drug resistances, and chronic diseases, among other clearances.

Discover efficient phase analysis and microstructural insights to optimize materials for aerospace, automotive, and battery applications.